P. aeruginosa type III secreted effectors in corneal disease
角膜疾病中铜绿假单胞菌 III 型分泌效应子
基本信息
- 批准号:9115162
- 负责人:
- 金额:$ 39.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-01-01 至 2020-07-31
- 项目状态:已结题
- 来源:
- 关键词:1-Phosphatidylinositol 3-KinaseADP Ribose TransferasesADP ribosylationAnti-Bacterial AgentsApoptosisBacteriaBlindnessC-terminalCalciumCategoriesCell physiologyCellsClinicalConfocal MicroscopyContact LensesCorneaCorneal DiseasesCorneal StromaCorneal UlcerCytoplasmic GranulesDataDevelopmentEnzymesExotoxinsEye InfectionsFundingGrantHealthHumanImmuneImmune systemInduction of ApoptosisInfectionInfection preventionInhibition of ApoptosisInjection of therapeutic agentInvadedKeratitisLeadLeftLinkMediatingMolecularMonitorN-terminalNADPH OxidaseNeutrophil InfiltrationOrganismOutcomeOxygenPathogenesisPathway interactionsPhagocytosisPhagocytosis InhibitionPhagosomesPopulationProductionProteinsPseudomonasPseudomonas aeruginosaReactive Oxygen SpeciesReportingResearchResolutionRespiratory BurstRoleSignal PathwaySyringesSystemTestingTherapeuticType III Secretion System PathwayVirulenceWorkantimicrobialantimicrobial peptidebactericidebasecell typecombatcorneal epitheliumcytotoxicdesignin vivokillingsmeltingmicrobialneutrophilnovelnovel strategiespreventprogramsresearch studyresponserhotargeted treatmenttherapeutic target
项目摘要
DESCRIPTION (provided by applicant): P. aeruginosa is one of the most common causes of microbial keratitis, both in the U.S. and worldwide. P. aeruginosa uses a molecular syringe, called type III secretion system, to avoid killing by infiltrating neutrophils, thereby preventing clearance of the infection. P. aeruginosa isolates can be divided into two categories, based on the effector proteins these strains inject using their type III secretion system. "Cytotoxic" isolaes produce ExoU and ExoT, whereas "invasive" isolates produce ExoS and ExoT. We recently discovered that invasive isolates of P. aeruginosa use ExoS and ExoT to inhibit the two major bactericidal functions of neutrophils, reactive oxygen species production and fusion of antimicrobial granules with the bacteria-containing phagosome. Accordingly, the proposed program of research will examine the molecular pathways in neutrophils that ExoS and ExoT inhibit to block reactive oxygen species production (Aim 1) and granule fusion (Aim 2). We will also determine whether injection of ExoS- and ExoT into neutrophils can promote corneal infection on a population level, by inactivating neutrophils through induction of apoptosis, or effector-mediated inhibition of phagocytosis. Here the first phagocytosed bacterium would act as a poison pill, inactivating the neutrophil, thereby allowing the other bacteria to thrive (Aim 3). Our program of research is therefore poised to discover multiple cellular processes that are inhibited by P. aeruginosa, and uncover new approaches to therapeutically intervene in the infection.
描述(由适用提供):铜绿假单胞菌是在美国和全球范围内最常见的微生物角膜炎原因之一。铜绿假单胞菌使用称为III型分泌系统的分子注射器,以避免通过浸润中性粒细胞杀死,从而防止感染清除。铜绿假单胞菌分离株可以根据效应蛋白使用其III型分泌系统注入两类。 “细胞毒性”的分离菌产生了外观和外观,而“入侵”分离株产生了exos和Exot。我们最近发现,铜绿假单胞菌的侵入性分离株使用外ex和Exot抑制中性粒细胞的两个主要细菌功能,活性氧的产生以及抗菌颗粒与含细菌的吞噬体的融合。彼此之间,拟议的研究计划将检查中性粒细胞中的分子途径,这些嗜中性粒细胞抑制了抑制可阻止活性氧的产生(AIM 1)和颗粒融合(AIM 2)。我们还将通过通过诱导凋亡诱导中性粒细胞或效应子介导的抑制吞噬作用来确定将外虫和外孔注射到中性粒细胞中可以在人群水平上促进中心感染。在这里,第一个吞噬细胞的细菌将充当毒药,使中性粒细胞失活,从而使其他细菌繁殖(AIM 3)。因此,我们的研究计划被毒死,以发现铜绿假单胞菌抑制的多种细胞过程,并发现了治疗方法干预感染的新方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Arne Rietsch其他文献
Arne Rietsch的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Arne Rietsch', 18)}}的其他基金
Host cell factors controlling type III secretion effector translocation
控制III型分泌效应器易位的宿主细胞因子
- 批准号:
10416972 - 财政年份:2022
- 资助金额:
$ 39.63万 - 项目类别:
Host cell factors controlling type III secretion effector translocation
控制III型分泌效应器易位的宿主细胞因子
- 批准号:
10586145 - 财政年份:2022
- 资助金额:
$ 39.63万 - 项目类别:
Development of recombinase-based tools to study established infections
开发基于重组酶的工具来研究已确定的感染
- 批准号:
10201472 - 财政年份:2020
- 资助金额:
$ 39.63万 - 项目类别:
Development of recombinase-based tools to study established infections
开发基于重组酶的工具来研究已确定的感染
- 批准号:
10040615 - 财政年份:2020
- 资助金额:
$ 39.63万 - 项目类别:
Type III Secretion Translocon Structure and Function
III型分泌易位子的结构和功能
- 批准号:
8701601 - 财政年份:2014
- 资助金额:
$ 39.63万 - 项目类别:
P. aeruginosa type III secreted effectors in corneal disease
角膜疾病中铜绿假单胞菌 III 型分泌效应子
- 批准号:
8404007 - 财政年份:2012
- 资助金额:
$ 39.63万 - 项目类别:
P. aeruginosa type III secreted effectors in corneal disease
角膜疾病中铜绿假单胞菌 III 型分泌效应子
- 批准号:
8962457 - 财政年份:2012
- 资助金额:
$ 39.63万 - 项目类别:
P. aeruginosa type III secreted effectors in corneal disease
角膜疾病中铜绿假单胞菌 III 型分泌效应子
- 批准号:
8217524 - 财政年份:2012
- 资助金额:
$ 39.63万 - 项目类别:
P. aeruginosa type III secreted effectors in corneal disease
角膜疾病中铜绿假单胞菌 III 型分泌效应子
- 批准号:
8597435 - 财政年份:2012
- 资助金额:
$ 39.63万 - 项目类别:
相似国自然基金
ADP-核糖基转移酶SpyA在抗化脓链球菌固有免疫反应中的分子机制研究
- 批准号:82371785
- 批准年份:2023
- 资助金额:51 万元
- 项目类别:面上项目
ADP核糖基转移酶SIRT4通过调控MAT2A依赖的蛋氨酸代谢抑制肝癌的机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
ADP核糖基转移酶SIRT4通过调控MAT2A依赖的蛋氨酸代谢抑制肝癌的机制研究
- 批准号:82273259
- 批准年份:2022
- 资助金额:52.00 万元
- 项目类别:面上项目
相似海外基金
The Anti-Autophagy Arsenal of Legionella pneumophila
嗜肺军团菌的抗自噬阿森纳
- 批准号:
10679185 - 财政年份:2023
- 资助金额:
$ 39.63万 - 项目类别:
Inflammasome-mediated corneal epithelial cell defenses inhibited by pathogenic bacteria
致病菌抑制炎症小体介导的角膜上皮细胞防御
- 批准号:
10688090 - 财政年份:2022
- 资助金额:
$ 39.63万 - 项目类别:
The non-catalytic function of PARP2 in DNA repair and cancer therapy
PARP2在DNA修复和癌症治疗中的非催化功能
- 批准号:
10641934 - 财政年份:2022
- 资助金额:
$ 39.63万 - 项目类别:
The non-catalytic function of PARP2 in DNA repair and cancer therapy
PARP2在DNA修复和癌症治疗中的非催化功能
- 批准号:
10540084 - 财政年份:2022
- 资助金额:
$ 39.63万 - 项目类别: